Rash News and Research

RSS

New assessment framework improves evaluation of cutaneous chronic graft-versus-host disease

An international task force of medical experts recently proposed major revisions to the way doctors measure treatment success for a common–and often severe–skin complication of stem cell transplantation.

24 Jan 2026

Shingles vaccination may slow biological aging in older adults

Shingles vaccination not only protects against the disease but may also contribute to slower biological aging in older adults, according to a new USC Leonard Davis School of Gerontology study.

20 Jan 2026

Novel antibody shows promise in overcoming resistance to cancer immunotherapy

According to a Phase I study led by researchers at The University of Texas MD Anderson Cancer Center, published today in Nature Medicine, the novel monoclonal antibody linavonkibart demonstrated the potential to overcome treatment resistance to anti-PD-1 immune checkpoint inhibitors in multiple cancer types.

13 Jan 2026

Mpox clade Ib transmitted in a healthcare setting outside Africa

Mpox is a viral disease usually transmitted from animals to humans and symptoms include fever and skin rashes. In 2023, a new variant of monkeypox virus (MPXV), called clade Ib, emerged in Kamituga in the Democratic Republic of the Congo.

19 Dec 2025

EULAR proposes new guidance to assess disease activity in adult-onset Still’s disease

EULAR - The European Alliance of Associations for Rheumatology - has identified an unmet clinical need around the assessment of disease activity in people with adult-onset Still's disease.

12 Dec 2025

Study explains why mpox cases can appear weeks after exposure

Mpox virus clade Ib shows a longer and more variable incubation period than previously characterized clades, with symptom onset extending well beyond 21 days in a substantial minority of cases. Incubation varies by transmission route, with shorter intervals after sexual exposure and longer periods following nonsexual community transmission, raising implications for surveillance and postexposure guidance.

9 Dec 2025

Shingles vaccine may benefit individuals already diagnosed with dementia, new study finds

An unusual public health policy in Wales may have produced the strongest evidence yet that a vaccine can reduce the risk of dementia.

2 Dec 2025

Experimental drug engasertib shows promise for treating inherited bleeding disorder

Hereditary hemorrhagic telangiectasia (HHT) is the second most common inherited bleeding disorder worldwide, affecting 1 in 3,800 persons.

26 Nov 2025

Testing nicotinamide riboside as a potential aid for long COVID recovery

Chao-Yi Wu, PhD, OT, from the Department of Neurology and Edmarie Guzmán-Vélez, PhD, of the Department of Psychiatry at Mass General Brigham, are the lead and senior authors of a paper published in eClinicalMedicine, "Effects of Nicotinamide Riboside on NAD+ Levels, Cognition, and Symptom Recovery in Long-COVID: A Randomized Controlled Trial."

14 Nov 2025

Innovative test for Lyme disease offers hope for faster diagnosis

Researchers at Dartmouth Hitchcock Medical Center have developed a way to diagnose Lyme disease earlier and more accurately than traditional testing methods.

14 Nov 2025

Cesarean births do not raise infant allergy risk in major Japanese cohort study

In a large Japanese birth cohort, cesarean delivery was not linked to higher risks of eczema, wheezing, atopic dermatitis, or asthma in infants at one year of age. Emergency cesarean delivery was even associated with a modest reduction in eczema, suggesting that mode of birth alone may not drive early-life allergic disease.

13 Nov 2025

Researchers confirm first death linked to tick-induced meat allergy

University of Virginia School of Medicine researchers have identified the first death caused by what is commonly called the "meat allergy" being spread by ticks.

13 Nov 2025

Dermatological symptoms could signal higher risk in psychiatric patients

Scientists have discovered that mental health patients who have skin conditions may be more at risk of worse outcomes, including suicidality and depression.

13 Oct 2025

Understanding the impact of chikungunya on children

Chikungunya is a vector-borne disease that affects both adults and children. While global efforts are ongoing to tackle chikungunya in adults, progress in addressing pediatric chikungunya remains inadequate.

10 Oct 2025

Study links skin conditions to worse outcomes in mental health patients

Scientists have discovered that mental health patients who have skin conditions may be more at risk of worse outcomes, including suicidality and depression.

9 Oct 2025

Intranasal adrenaline can be as effective as the EpiPen

Instead of stabbing yourself, or someone else, in the thigh with a needle to deliver a dose of adrenaline to counter anaphylactic shock, would it not be easier to use a nasal spray instead?

30 Sep 2025

Survey shows low public concern despite rising West Nile virus infections in the U.S.

West Nile virus is the leading cause of mosquito-borne illness in the continental United States. As of Sept. 23, over 1,100 human cases of West Nile disease have been reported across 42 states, according to the U.S. Centers for Disease Control and Prevention (CDC), including nearly 750 cases of the more serious neuroinvasive form which affects the brain.

26 Sep 2025

Scientists outline how future therapies could change type 1 diabetes care

Researchers writing in The Lancet review breakthroughs in type 1 diabetes treatment, from immunotherapies that delay onset to stem-cell β-cell replacement and automated insulin delivery. They stress that equitable access, validated surrogate endpoints, and scalable technologies are crucial for lasting impact.

24 Sep 2025

Breakthrough findings point to future treatments for juvenile dermatomyositis

Children with a rare, debilitating muscle disease could benefit from the findings of new research by experts at UCL and Great Ormond Street Hospital (GOSH).

11 Sep 2025

Subcutaneous amivantamab plus lazertinib yields high response in EGFR-mutant lung cancer

A new analysis from the PALOMA-2 study presented today shows that subcutaneous administration of amivantamab every four weeks (Q4W), in combination with daily oral lazertinib, yields a high objective response rate in patients with previously untreated EGFR-mutated advanced non-small cell lung cancer (NSCLC).

10 Sep 2025